No Data
No Data
Express News | Gain Therapeutics Announces Positive Topline Results From the Phase 1 Clinical Trial of GT-02287, a Novel Gcase-Targeting Small Molecule Therapy for Parkinson’s Disease
Small-Cap Gain Therapeutics Stock Falls On Phase 1 Data From Its Lead Asset For Parkinson's Disease
Express News | Gain Therapeutics Shares Are Trading Lower. The Company Announced Positive From the Phase 1 Study Conducted to Evaluate the Safety, Tolerability and Pharmacokinetics of GT-02287
Gain Slips After Early-stage Data for Parkinson's Therapy
Express News | Gain Therapeutics Inc - GT-02287 Phase 1B Trial Starts Q4 2024
Gain Therapeutics Announces Positive Topline Results From the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease
No Data